Day One Biopharmaceuticals (NASDAQ:DAWN) Downgraded by JonesTrading to “Hold”

JonesTrading lowered shares of Day One Biopharmaceuticals (NASDAQ:DAWN) from a buy rating to a hold rating in a report issued on Friday, Marketbeat.com reports. JonesTrading currently has $21.50 price objective on the stock, up from their prior price objective of $20.00.

Other analysts have also issued reports about the company. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. TD Cowen downgraded Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $25.56.

Day One Biopharmaceuticals Trading Up 65.9%

NASDAQ DAWN traded up $8.42 during trading on Friday, reaching $21.20. The company’s stock had a trading volume of 78,369,097 shares, compared to its average volume of 2,410,501. The firm has a 50 day moving average price of $11.10 and a 200 day moving average price of $9.05. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $21.23. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -20.58 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. On average, equities analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 15,459 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer directly owned 204,603 shares in the company, valued at $2,373,394.80. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Vasconcelles sold 2,728 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares in the company, valued at $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,461 shares of company stock valued at $422,948 over the last ninety days. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Large investors have recently modified their holdings of the company. Rubric Capital Management LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $23,808,000. Vestal Point Capital LP boosted its position in shares of Day One Biopharmaceuticals by 94.4% during the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after purchasing an additional 2,525,000 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $10,719,000. Mak Capital One LLC acquired a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $10,212,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $9,758,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.